$16.70
▲ +1.9% Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Generate Biomedicines Shares Fall Following Q2 Financial Results
Overview
52-week range
$11
$23
49% of range
Avg surprise (last 1)
-122.9%
Avg reaction (last 1)
-11.2%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.52 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-1.07 | $-0.48 | -122.9% | — | -11.2% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-1.94 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-1.62 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | $6M | $7M | — | $10M | $9M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-72M | $-64M | — | $-60M | $-48M |
| Net income | $-67M | $-61M | — | $-52M | $-42M |
| EPS (diluted) | $-0.52 | $-1.07 | — | $-1.94 | $-1.62 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $135M | $161M | $122M | $154M | $221M |
| Inventory | — | — | — | — | — |
| Total current assets | $470M | $535M | $234M | — | — |
| Total assets | $562M | $626M | $330M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $106M | $111M | $142M | — | — |
| Total equity | $456M | $515M | $-616M | $-518M | $-471M |
Implied volatility — last 90 days
No IV snapshots yet for GENB.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.